Mais conteúdo relacionado
Semelhante a Novartis and IPCA Financial Analysis (20)
Mais de Shahzad Khan (20)
Novartis and IPCA Financial Analysis
- 7. Management Discussion & Analysis IPCA Performance Overview Verticals 2006 (Crs) 2005 (Crs) Formulations 501.29 447.59 API & Intermediates 247.76 228.68 Net Total Sales 749.05 676.27
- 10. Company Novartis Ipca (Rs. / Crores) 2006 2005 2006 2005 SOURCE OF FUNDS Shareholders Funds 338 284 370 326 Loan Funds 6 7 197 221 Provision for Deferred Taxation (net) 48 43 Total 344 291 615 590 APPLICATION OF FUNDS Fixed Asset 10 22 374 323 Investments 7 48 4 3 Deferred Taxation 11 9 Current Assets: 449 329 358 361 Less : Current Liabilities 133 116 121 97 Net Current Assets 316 213 237 263 Pre-Operative Expenses (w/off) 0 Total 344 291 615 590
- 23. 3. Return on Capital Employed 4. Net Profit Ratio Profitability Ratios